These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study. Gonzalez-Martinez A; Bose G; Lokhande H; Saxena S; Healy BC; Polgar-Turcsanyi M; Weiner HL; Chitnis T J Neuroinflammation; 2023 Jun; 20(1):136. PubMed ID: 37264432 [TBL] [Abstract][Full Text] [Related]
12. Temporal variability of serum miR-191, miR-223, miR-128, and miR-24 in multiple sclerosis: A 4-year follow-up study. Vistbakka J; Sumelahti ML; Lehtimäki T; Hagman S J Neurol Sci; 2022 Nov; 442():120395. PubMed ID: 36084364 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of miR-125a-5p and miR-218-5p in Peripheral Blood Mononuclear Cells of Patients with Relapsing-Remitting Multiple Sclerosis. Mosarrezaii Aghdam A; Rezaei S; Zarza Nalivan F; Babaie F; Amiri Nikpour MR; Torkamandi S Immunol Invest; 2022 Jul; 51(5):1149-1161. PubMed ID: 33866949 [TBL] [Abstract][Full Text] [Related]
14. miR-181a-5p is a potential candidate epigenetic biomarker in multiple sclerosis. Edgünlü TG; Yılmaz ŞG; Emre U; Taşdelen B; Kuru O; Kutlu G; Erdal ME Genome; 2022 Nov; 65(11):547-561. PubMed ID: 36103723 [TBL] [Abstract][Full Text] [Related]
15. Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients. Arisi I; Malimpensa L; Manzini V; Brandi R; Gosetti di Sturmeck T; D'Amelio C; Crisafulli S; Ferrazzano G; Belvisi D; Malerba F; Florio R; Pascale E; Soreq H; Salvetti M; Cattaneo A; D'Onofrio M; Conte A Front Immunol; 2023; 14():1234869. PubMed ID: 38152407 [TBL] [Abstract][Full Text] [Related]
16. Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression. Ibrahim SH; El-Mehdawy KM; Seleem M; El-Sawalhi MM; Shaheen AA J Neuroimmunol; 2020 Oct; 347():577356. PubMed ID: 32781341 [TBL] [Abstract][Full Text] [Related]
17. Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting multiple sclerosis. Giuliani A; Lattanzi S; Ramini D; Graciotti L; Danni MC; Procopio AD; Silvestrini M; Olivieri F; Sabbatinelli J Mult Scler Relat Disord; 2021 Sep; 54():103126. PubMed ID: 34243103 [TBL] [Abstract][Full Text] [Related]
18. Extracellular miR-145, miR-223 and miR-326 expression signature allow for differential diagnosis of immune-mediated neuroinflammatory diseases. Sharaf-Eldin WE; Kishk NA; Gad YZ; Hassan H; Ali MAM; Zaki MS; Mohamed MR; Essawi ML J Neurol Sci; 2017 Dec; 383():188-198. PubMed ID: 29246612 [TBL] [Abstract][Full Text] [Related]
19. miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis. Muñoz-San Martín M; Gómez I; Quiroga-Varela A; Gonzalez-Del Río M; Robles Cedeño R; Álvarez G; Buxó M; Miguela A; Villar LM; Castillo-Villalba J; Casanova B; Quintana E; Ramió-Torrentà L Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724195 [TBL] [Abstract][Full Text] [Related]
20. Upregulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients. Zanoni M; Orlandi E; Rossetti G; Turatti M; Calabrese M; Gomez Lira M; Gajofatto A Acta Neurol Scand; 2020 Nov; 142(5):511-516. PubMed ID: 32432792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]